Promakhos Therapeutics GTM brain

category

market profile

• text: Crohn's and other chronic inflammatory diseases have patients who do not maintain benefit from existing therapies; the company is pursuing a preclinical oral candidate.
• text: Near-term traction depends on research funding, clinical validation and development partnerships rather than routine product sales.

personas

• title: Pharma business development leader, immunology
  pains:

  • Needs differentiated IBD assets with a clear mechanism and translatable evidence
  • Must assess development risk before committing to a partnership
• title: Gastroenterologist and IBD clinical investigator
  pains:

  • Patients can lose response to existing treatments
  • Needs evidence of safety and durable benefit before recommending a new mechanism
• title: Crohn's disease research foundation program director
  pains:

  • Must prioritize limited research grants toward credible patient impact
  • Needs milestones that demonstrate progress toward human studies

icp

• text: Pharmaceutical companies with immunology or gastroenterology development portfolios and capacity to license preclinical assets; a prospective partner profile, not a disclosed customer segment.
• text: IBD research foundations and academic medical centers supporting translational Crohn's research and clinical trials.

message pillars

• text: Ground discovery in human patient biology.
• text: Aim to address disease causes rather than symptoms alone.
• text: Restore the body's own inflammation control and healing.

objections

• objection: Is the therapy proven in people?
  response: It remains investigational; request preclinical data and the clinical development plan rather than assuming efficacy.
• objection: How is this different from existing immunosuppressants?
  response: The stated approach aims to restore immune function rather than suppress it; comparative outcomes require clinical testing.

competitors

• name: Abivax
  why: Develops an IBD drug candidate for the same treatment landscape.
• name: Palisade Bio
  why: Develops an investigational therapy for inflammatory bowel disease.

influencers

• name: Katerina Chatzi
  url: https://blog.startuppirate.com/p/developing-therapies-for-chronic
  why: Founder and CEO discusses the scientific approach and trial requirements.
• name: Jasper E. Neggers
  url: https://www.linkedin.com/in/jasperneggers
  why: Co-founder shares company research and funding updates.

keywords

• Crohn's disease drug development
• innate immunity Crohn's
• non immunosuppressive IBD treatment
• oral Crohn's therapy
• inflammatory bowel disease pipeline

voice

• scientific and accessible
• hopeful but development-focused
• patient-centered

signals

• text: An immunology portfolio team is looking for differentiated preclinical IBD assets or external innovation partnerships.
• text: A foundation announces funding for mucosal immunity or Crohn's translational research.

pricing

motion

channels

• LinkedIn
• research foundations
• industry events

confidence

Founders

• name: Katerina Chatzi
  title: Founder
  role: Founder
  bio: I believe we can discover unexpected things that can transform our lives. I have lived and performed research in 4 countries and 2 continents. Previously I was a postdoc at Harvard. I founded Promakhos because I think we have given to “autoimmune” diseases a grossly misleading name and we treat them in a primitive way. Promakhos means the first to enter a battle. In ancient Greece Promakhos was the strongest to put in the front line of an army so that they will not even have to start a battle.
• name: Jasper Edgar Neggers
  title: Founder
  role: Founder
  bio: CSO and co-founder of Promakhos. In high school, Jasper built a web-shop. He obtained a BSc, MSc and PhD in Biomedical Sciences from KU Leuven. He pioneered the use of XPO1 inhibitors for treating cancer and invented a CRISPR-directed evolution technology for drug target deconvolution. Jasper then joined the Dana-Farber Cancer Institute & Broad Institute of MIT and Harvard to identify and validate new drug targets for gastrointestinal cancers. Now, he develops drugs for chronic inflammation.